Whitehawk Therapeutics (WHWK) Cash & Equivalents (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of Cash & Equivalents data on file, last reported at $123.0 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 45.95% year-over-year to $123.0 million in Q1 2026; TTM through Mar 2026 was $123.0 million, a 45.95% decrease from a year earlier, with the FY2025 full-year figure at $37.6 million, up 31.04% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $123.0 million, up from $37.6 million in the prior quarter.
• Over the last five years, Cash & Equivalents for WHWK reached as high as $227.6 million in Q1 2025 and fell as low as $28.7 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $81.3 million across 5 years, with a median of $62.9 million in 2023.
• Across the five-year window, Cash & Equivalents tumbled 73.81% in 2022 and surged 323.15% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $39.0 million in 2022, then jumped by 61.17% to $62.9 million in 2023, then tumbled by 54.41% to $28.7 million in 2024, then jumped by 31.04% to $37.6 million in 2025, then surged by 227.41% to $123.0 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $123.0 million in Q1 2026, $37.6 million in Q4 2025, and $37.9 million in Q3 2025.